Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study

Biochemical and Biophysical Research Communications
Sonia ArouiAbderraouf Kenani

Abstract

One of the major obstacles which are opposed to the success of anticancer treatment is the cell resistance that generally develops after administration of commonly used drugs. In this study, we try to overcome the tumour cell resistance of doxorubicin (Dox) by developing a cell-penetrating peptide (CPP)-anticancer drug conjugate in aim to enhance its intracellular delivery and that its therapeutic effects. For this purpose, two cell-penetrating peptides, penetratin (pene) and tat, derived from the HIV-1 TAT protein, were chemically conjugated to Dox. The cytotoxicity, intracellular distribution and uptake were accessed in CHO cells (Chinese Hamster Ovarian carcinoma cells), HUVEC (Human Umbilical Vein Endothelial Cells), differentiated NG108.15 neuronal cell and breast cancer cells MCF7drug-sensitive or MDA-MB 231 drug-resistant cell lines. The conjugates showed different cell killing activity and intracellular distribution pattern by comparison to Dox as assessed respectively by MTT-based colorimetric cellular cytotoxicity assay, confocal fluorescence microscopy and FACS analysis. After treatment with 3 microM with Dox-CPPs for 2h, pene increase the Dox cytotoxicity by 7.19-fold in CHO cells, by 11.53-fold in HUVEC cells and b...Continue Reading

References

Jan 1, 1993·Annual Review of Biochemistry·M M Gottesman, I Pastan
Mar 1, 1996·General Pharmacology·D NielsenT Skovsgaard
Aug 8, 1998·Trends in Cell Biology·D DerossiA Prochiantz
Mar 23, 2001·Anti-cancer Drugs·M MazelJ Temsamani
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ulrich Massing, Stefan Fuxius
Jan 31, 2002·Annual Review of Medicine·Michael M Gottesman
Mar 26, 2002·Biochemical Pharmacology·Yvette van HensbergenHerbert M Pinedo
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·M BinaschiF Animati
Jun 19, 2004·Anti-cancer Drugs·Cédric CastexJamal Temsamani
Nov 30, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Giuseppina Di StefanoLuigi Fiume
Dec 3, 2004·Drug Discovery Today·Jamal Temsamani, Pierre Vidal
Jan 11, 2005·The Journal of Pathology·D B Longley, P G Johnston
Feb 16, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Martin HrubýKarel Ulbrich
Feb 22, 2005·Advanced Drug Delivery Reviews·Matjaz Zorko, Ulo Langel
Sep 3, 2005·Analytical Biochemistry·Külliki SaarUlo Langel
Apr 6, 2006·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·G Di StefanoM Bernardi
Jul 25, 2006·Current Opinion in Pharmacology·Maarja Mäe, Ulo Langel
Dec 19, 2006·The Journal of Clinical Investigation·Galina A GusarovaRobert H Costa
Jun 9, 2007·Biochemistry·André Ziegler, Joachim Seelig
Oct 20, 2007·The Journal of Pharmacology and Experimental Therapeutics·Fei ShenLeonard C Erickson
Jan 12, 2008·Journal of Pharmacological Sciences·Munetaka HiroseYoshifumi Tanaka

❮ Previous
Next ❯

Citations

Mar 30, 2013·International Journal of Pharmaceutics·Xiaoli LiuWeiyue Lu
Mar 22, 2012·The Journal of Biological Chemistry·Cathy PoillotMichel De Waard
May 24, 2012·International Journal of Nanomedicine·Nian-Qiu ShiXian-Rong Qi
Nov 26, 2013·Advanced Drug Delivery Reviews·Swati Biswas, Vladimir P Torchilin
Oct 19, 2014·BMC Cancer·Emilia Joanna OrzechowskaJoanna Trzcinska-Danielewicz
Sep 29, 2011·Drug Metabolism Reviews·Veronika HanušováLenka Skálová
Aug 26, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Nian-Qiu ShiYong Zhang
Feb 26, 2016·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Ewa AugustinZofia Mazerska
Nov 28, 2015·International Journal of Molecular Sciences·Pascale PerretMichel De Waard
Oct 9, 2015·Therapeutic Delivery·Jesús FominayaAngelita Rebollo
Mar 29, 2014·Biochimica Et Biophysica Acta·Céline TisseyreMichel De Waard
May 12, 2010·Biochemical and Biophysical Research Communications·Sonia ArouiAbderraouf Kenani
Apr 14, 2016·Proceedings of the National Academy of Sciences of the United States of America·Michel RonjatMichel De Waard
Jul 17, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Jianian ChenQi Shen
Nov 28, 2013·Pharmaceuticals·Céline TisseyreMichel De Waard
Feb 1, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Antonella BorrelliFranco M Buonaguro
Jan 26, 2018·Phytotherapy Research : PTR·Xiuxia LiLijuan Chen
Jul 25, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Eltayeb E M EidMohammed A Alshawsh
Apr 30, 2015·The Journal of Pharmacology and Experimental Therapeutics·Julia DurzyńskaAnna Goździcka-Józefiak
Sep 21, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Hongmei LiuXin Zhang
Jan 4, 2019·European Journal of Medicinal Chemistry·Hongtao Xu, Bo Liu
Oct 4, 2020·Life Sciences·Negin GhandhariyounSeyedeh Alia Moosavian
Apr 20, 2021·ACS Biomaterials Science & Engineering·Suguna PerumalIn Woo Cheong
Mar 23, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·John M AkuduguRoger W Howell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.